2024-03-28T18:10:51Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02016892
2022-02-22T07:18:47Z
1642838163960:1642838198944:1642838199408:1642838231050
1642838403551:1642838412624
Evaluation of candidate therapies using a patient-derived cervical cancer xenograft model
Nagayama-Urasoe, Chiaki
Umikawa, Masato
Asato, Tsuyoshi
Nagai, Yutaka
Aoki, Yoichi
Kariya, Ken-ichi
cervical cancer
patient-derived xenograft
gemcitabine
cediranib
salinomycin
Patient-derived xenograft (PDX) models are useful for preclinical evaluation of anticancer agents. However, establishing PDX models of cervical cancers are known to be challenging. We modified a protocol from the existing literature and established a model of an HPV16-positive squamous cell carcinoma on scid mice. The xenograft was positive for p16INK4a even after a passage, indicating the continued involvement of the E7 viral oncoprotein in abnormal cell growth. After 24 days of treatment with a nucleoside analog, gemcitabine, tumor growth was found to be suppressed in a dose-dependent manner, and the tumor became undetectable after high-dose treatment. Cediranib, an orally bioavailable inhibitor of neovascularization, reversed tumor growth until it was barely detectable. A hydrophobic cancer stem cell inhibitor, salinomycin, did not show any significant effect when used alone, but showed a tendency to act synergistically with low-dose gemcitabine. Although further procedural refinements are required, the model appeared to be useful for preclinical evaluation of various anticancer agents, including novel ones that target specific molecules.
論文
http://purl.org/coar/resource_type/c_6501
琉球医学会
Ryukyu Medical Association
VoR
1346-888X
AN10369445
琉球医学会誌 = Ryukyu Medical Journal
1-2
36
28
25
eng
open access
琉球医学会